A Trial of Hyperimmune Globulin to Prevent Congenital Cytomegalovirus Infection

 Primary cytomegalovirus (CMV) infection during pregnancy carries a risk of congenital infection and possible severe sequelae. There is no established intervention for preventing congenital CMV infection.

 In this multicenter, double-blind trial, pregnant women with primary CMV infection diagnosed before 24 weeks’ gestation were randomly assigned to receive a monthly infusion of CMV hyperimmune globulin (at a dose of 100 mg per kilogram of body weight) or matching placebo until delivery. The primary outcome was a composite of congenital CMV infection or fetal or neonatal death if CMV testing of the fetus or neonate was not performed.

Among pregnant women, administration of CMV hyperimmune globulin starting before 24 weeks’ gestation did not result in a lower incidence of a composite of congenital CMV infection or perinatal death than placebo.


Comments

Popular posts from this blog

Variant PNLDC1, Defective piRNA Processing, and Azoospermia

Association Between Menstrual Cycle Length and Coronavirus Disease 2019 (COVID-19) Vaccination.

Women's Experience of Their First Sexual Encounter After Pelvic Reconstructive Surgery